{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:50:25Z","timestamp":1790297425737,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.schres.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T04:53:57Z","timestamp":1621227237000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension"],"prefix":"10.1016","volume":"232","author":[{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard L.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"DiPetrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasudev","family":"Bhupathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Yagoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Hopkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.schres.2021.04.009_bb0005","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.schres.2021.04.009_bb0010","first-page":"11","article-title":"Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration adverse event database: a systematic Bayesian signal detection analysis","volume":"42","author":"Baker","year":"2009","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.schres.2021.04.009_bb0015","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2021.04.009_bb0020","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4088\/JCP.10m06497","article-title":"The impact of the clinical antipsychotic trials of intervention effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state","volume":"73","author":"Berkowitz","year":"2012","journal-title":"J. Clin. Psychiatry."},{"issue":"4","key":"10.1016\/j.schres.2021.04.009_bb0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/0269881112473789","article-title":"Weight change by baseline BMI from three-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database","volume":"27","author":"Bushe","year":"2013","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2021.04.009_bb0030","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.mayocp.2013.11.011","article-title":"A pooled analysis of waist circumference and mortality in 650,000 adults","volume":"89","author":"Cerhan","year":"2014","journal-title":"Mayo Clin. Proc."},{"issue":"9799","key":"10.1016\/j.schres.2021.04.009_bb0035","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.schres.2021.04.009_bb0040","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study","volume":"177","author":"Correll","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2021.04.009_bb0045","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1177\/0269881119856850","article-title":"Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and nonhuman primates","volume":"33","author":"Cunningham","year":"2019","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2021.04.009_bb0050","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1096\/fj.09-143610","article-title":"Kappa-opioid receptors control the metabolic response to a high-energy diet in mice","volume":"24","author":"Czyzyk","year":"2010","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.schres.2021.04.009_bb0055","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1096\/fj.12-208041","article-title":"Mice lacking delta-opioid receptors resist the development of diet-induced obesity","volume":"26","author":"Czyzyk","year":"2012","journal-title":"FASEB J."},{"issue":"10","key":"10.1016\/j.schres.2021.04.009_bb0060","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4088\/JCP.v63n1010","article-title":"Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database","volume":"63","author":"Gianfrancesco","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2021.04.009_bb0065","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/0974-7788.76794","article-title":"Understanding survival analysis: Kaplan-Meier estimate","volume":"1","author":"Goel","year":"2010","journal-title":"Int. J. Ayurveda. Res."},{"key":"10.1016\/j.schres.2021.04.009_bb0070","series-title":"CGI Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology","first-page":"217","author":"Guy","year":"1976"},{"issue":"4","key":"10.1016\/j.schres.2021.04.009_bb0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","article-title":"Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results","volume":"17","author":"Haro","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"10202","key":"10.1016\/j.schres.2021.04.009_bb0080","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"9618","key":"10.1016\/j.schres.2021.04.009_bb0085","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"282","key":"10.1016\/j.schres.2021.04.009_bb0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"issue":"2","key":"10.1016\/j.schres.2021.04.009_bb0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2021.04.009_bb0100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2021.04.009_bb0105","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/wps.20632","article-title":"Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons","volume":"18","author":"Kishimoto","year":"2019","journal-title":"World Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2021.04.009_bb0110","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archpsyc.59.11.1021","article-title":"An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients","volume":"59","author":"Koro","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2021.04.009_bb0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2021.04.009_bb0120","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.mp.4002136","article-title":"How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials","volume":"14","author":"Leucht","year":"2009","journal-title":"Mol. Psychiatry"},{"issue":"9896","key":"10.1016\/j.schres.2021.04.009_bb0125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.schres.2021.04.009_bb0130","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.schres.2021.04.009_bb0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","article-title":"Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia","volume":"176","author":"Martin","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2021.04.009_bb0140","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2021.04.009_bb0145","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12769","article-title":"Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia: outcomes from the randomized, phase 3 ENLIGHTEN-1 study","volume":"81","author":"Potkin","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2021.04.009_bb0150","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hep.20081","article-title":"Hy's law","volume":"39","author":"Reuben","year":"2004","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.schres.2021.04.009_bb0155","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1055\/s-0030-1248313","article-title":"Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder","volume":"43","author":"Schoemaker","year":"2010","journal-title":"Pharmacopsychiatry."},{"issue":"3","key":"10.1016\/j.schres.2021.04.009_bb0160","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/JCP.0000000000000320","article-title":"Use of remifentanil in a novel clinical paradigm to characterize onset and duration of opioid blockade by samidorphan, a potent mu-receptor antagonist","volume":"35","author":"Shram","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2021.04.009_bb0165","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.schres.2017.10.014","article-title":"A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers","volume":"195","author":"Silverman","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2021.04.009_bb0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"12","key":"10.1016\/j.schres.2021.04.009_bb0175","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.2337\/diabetes.54.12.3510","article-title":"Resistance to diet-induced obesity in mu-opioid receptor-deficient mice: evidence for a \u201cthrifty gene\u201d","volume":"54","author":"Tabarin","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.schres.2021.04.009_bb0180","unstructured":"World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. 2011. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK304267\/pdf\/Bookshelf_NBK304267.pdf. (Accessed: February 1, 2021)."},{"key":"10.1016\/j.schres.2021.04.009_bb0185","first-page":"1","article-title":"Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study","author":"Yagoda","year":"2020","journal-title":"CNS Spectr."},{"issue":"2","key":"10.1016\/j.schres.2021.04.009_bb0190","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/S0033291714001305","article-title":"A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania","volume":"45","author":"Yildiz","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2021.04.009_bb0195","unstructured":"Zyprexa [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421001547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421001547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:41:51Z","timestamp":1760298111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996421001547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":39,"alternative-id":["S0920996421001547"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2021.04.009","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}